Merit Medical Systems (NasdaqGS:MMSI) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Merit Medical Systems to reach your target.
Based on historical returns, we believe that Merit Medical Systems can grow its free cash at a rate of about 3%. That's positive!
| Advantages | Disadvantages | Neutral |
|---|---|---|
|
|
|
| MMSI Price (Merit Medical Systems stock price per share) |
$84.34 | |
|
|
MMSI Fair Price (based on intrinsic value) |
$38.86 |
| MMSI Safety Price (based on a variable margin of safety) | $25.26 | |
|
Try your own return
The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value. Value per share: |
||
| PE Ratio versus Sector | 56% higher than other Healthcare stocks | |
| PE Ratio versus Industry | 467% higher than other Medical Devices stocks | |
| Cash Yield | 1.07% | |
| Free Cash Flow Jitter | 72% | |
No open-market insider buys or sells are recorded for the last 12 months.
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 3,997,363 shares shorted. With 58,508,239 shares available for purchase and an average trading volume over the past 10 trading days of 497,450, it would take at least 8.0 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
Each year names the SEC filer that reported it, so a change of filer shows up here.
| Fiscal year | SEC filer (CIK) | Free cash flow (USD millions) |
|---|---|---|
| 2009 | 856982 | 11.6 |
| 2010 | 856982 | 13.7 |
| 2011 | 856982 | 0.2 |
| 2012 | 856982 | 5.4 |
| 2013 | 856982 | 6.3 |
| 2014 | 856982 | 5.1 |
| 2015 | 856982 | 15.8 |
| 2016 | 856982 | 5.2 |
| 2017 | 856982 | 19.5 |
| 2018 | 856982 | 42.5 |
| 2019 | 856982 | 25 |
| 2020 | 856982 | 113 |
| 2021 | 856982 | 96.4 |
| 2022 | 856982 | 62.2 |
| 2023 | 856982 | 98.9 |
| 2024 | 856982 | 183 |
| 2025 | 856982 | 253 |
Download the yearly data as CSV.
How to read this: what free cash flow is, why earnings matter.
Over the 15 fiscal years from 2009 to 2025 with positive net income, operating cash flow totaled $1,479 million against net income of $683 million, or 2.17 times. Net income was negative in 1 of the 16 years, and those years are left out of the ratio.
In 2025, operating cash flow was 2.31 times net income, compared with 1.70 times for the earliest three years (2009 to 2011).
In 2025, capital expenditures were $81.7 million, 27.5% of operating cash flow of $297 million, which leaves an estimated $216 million after capex. Across the 16 years with reported capex, it averaged 44.4% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2009 | 22.5 | 30.1 | 18.5 | 1.33 |
| 2010 | 12.5 | 34.8 | 23.6 | 2.79 |
| 2011 | 23 | 34 | 59.2 | 1.48 |
| 2013 | 16.6 | 51.4 | 59.5 | 3.10 |
| 2014 | 23 | 53.3 | 34.2 | 2.32 |
| 2015 | 23.8 | 69.5 | 51 | 2.92 |
| 2016 | 20.1 | 53.6 | 32.8 | 2.66 |
| 2017 | 27.5 | 62.7 | 38.6 | 2.28 |
| 2018 | 42 | 86.5 | 63.3 | 2.06 |
| 2019 | 5.5 | 77.8 | 78.2 | 14.27 |
| 2020 | -9.8 | 165 | 46 | n/a |
| 2021 | 48.5 | 147 | 27.9 | 3.04 |
| 2022 | 74.5 | 114 | 45 | 1.53 |
| 2023 | 94.4 | 145 | 34.3 | 1.54 |
| 2024 | 120 | 221 | 35.1 | 1.83 |
| 2025 | 128 | 297 | 81.7 | 2.31 |
How to read this: earnings and margins.
Revenue was $257 million in 2009 and $1,516 million in 2025, a compound annual growth rate of 11.7% over 16 years.
Revenue rose 11.8% from 2024 to 2025.
Our estimated free cash flow was $253 million in 2025, 16.7% of revenue. In 2009 the estimated margin was 4.5%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2009 | 257 | 11.6 | 4.5% |
| 2010 | 297 | 13.7 | 4.6% |
| 2011 | 359 | 0.2 | 0.1% |
| 2016 | 604 | 5.2 | 0.9% |
| 2017 | 728 | 19.5 | 2.7% |
| 2018 | 883 | 42.5 | 4.8% |
| 2019 | 995 | 25 | 2.5% |
| 2020 | 964 | 113 | 11.8% |
| 2021 | 1,075 | 96.4 | 9.0% |
| 2022 | 1,151 | 62.2 | 5.4% |
| 2023 | 1,257 | 98.9 | 7.9% |
| 2024 | 1,357 | 183 | 13.5% |
| 2025 | 1,516 | 253 | 16.7% |
How to read this: how debt and assets are compared, the current ratio.
In 2025, cash and equivalents were $446 million against total liabilities of $1,102 million, or 40.5% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 41.0% of total assets in 2025, compared with 36.2% in 2010, an increase of 4.8 percentage points.
Stockholders equity was $1,584 million in 2025, compared with $219 million in 2009, a rise of 624.1%.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 12.6% in 2025. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2009 | 272 | 6.1 | n/a | 219 |
| 2010 | 369 | 3.7 | 134 | 236 |
| 2011 | 447 | 10.1 | 89.9 | 357 |
| 2012 | 705 | 9.7 | 324 | 382 |
| 2013 | 728 | 7.5 | 323 | 406 |
| 2014 | 747 | 7.4 | 312 | 435 |
| 2015 | 779 | 4.2 | 313 | 466 |
| 2016 | 943 | 19.2 | 445 | 498 |
| 2017 | 1,112 | 32.3 | 435 | 676 |
| 2018 | 1,620 | 67.4 | 687 | 933 |
| 2019 | 1,757 | 44.3 | 807 | 950 |
| 2020 | 1,664 | 56.9 | 706 | 959 |
| 2021 | 1,648 | 67.8 | 608 | 1,040 |
| 2022 | 1,664 | 58.4 | 520 | 1,144 |
| 2023 | 2,325 | 587 | 1,123 | 1,202 |
| 2024 | 2,419 | 377 | 1,039 | 1,379 |
| 2025 | 2,686 | 446 | 1,102 | 1,584 |
How to read this: discounted cash flow, intrinsic value.
At today's price of $84.34, our model's value equals that price if free cash flow grows an average of 23.7 percent a year over the 10 projection years. Our model assumes 2.7 percent a year for this stock, so the price implies growth of 23.7 percent, which is above the 2.7 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.
At 23.7 percent a year, free cash flow would grow about 8.4 times over the 10 years.
The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.
The model starts from the company's average free cash flow of $54 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.
The baseline is the company's average free cash flow, and cyclical companies can mislead it.
| Case | Price per share | Average annual free cash flow growth |
|---|---|---|
| 20 percent below the current price | $67.47 | 19.0% |
| Current price | $84.34 | 23.7% |
| 20 percent above the current price | $101.21 | 27.3% |
| Our model (stored fair price) | $38.86 | 2.7% |
Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.
Every one of the 17 fiscal years we have for Merit Medical Systems under its current filer shows positive free cash flow.
Free cash flow from the first three years of data averaged $8.5 million, and from the last three $178 million: a sharp rise.
Year-to-year variability in free cash flow is volatile, measured at 72%.
At $84.34, Merit Medical Systems trades above our fair value estimate of $38.86.
No dividend yield is recorded for Merit Medical Systems in our data.
Before you act on any of this, read what a margin of safety means and check the company's own filings.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 56% above the average for stocks in the Healthcare sector.
Its trailing P/E ratio is 467% above the average for stocks in the Medical Devices industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Medical Devices industry, the ones closest in market capitalization to Merit Medical Systems, limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| Merit Medical Systems (MMSI) | 5,053 | 31.6 | - | 1.1% | 117% above |
| LivaNova PLC (LIVN) | 4,998 | 26.0 | - | - | 317% above |
| Haemonetics Corporation (HAE) | 5,472 | 53.2 | - | 1.7% | 132% above |
| Integer Holdings Corporation (ITGR) | 4,317 | 42.6 | - | - | 147% above |
| ICU Medical (ICUI) | 4,315 | 72.2 | - | 1.4% | 29% above |
| Teleflex Incorporated (TFX) | 6,408 | 79.6 | 0.8% | 5.6% | 24% below |
| UFP Technologies (UFPT) | 2,253 | 29.7 | - | 0.1% | 395% above |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 856982.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: MMSI annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Merit Medical Systems have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to MMSI: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
How Does Portfolio Churning Affect Your Returns?
Insider Buying as a Conviction Signal
What is Market Capitalization?
What is Cash Return on Invested Capital?